Psoriasis and Cardiovascular Disease: A Narrative Review

키워드

참고문헌 (108)

1. Dowlatshahi EA, "Markers of systemic inflammation in psoriasis : a systematic review and metaanalysis", Br J Dermatol, 169, pp.266~282 (2013)
2. Michalek IM, "A systematic review of worldwide epidemiology of psoriasis", J Eur Acad Dermatol Venereol, 31, pp.205~212 (2017)
3. Neimann AL, "Prevalence of cardiovascular risk factors in patients with psoriasis", J Am Acad Dermatol, 55, pp.829~835 (2006)
4. Johnson MA, "Clinical and histologic diagnostic guidelines for psoriasis : a critical review", Clin Rev Allergy Immunol, 44, pp.166~172 (2013)
5. Lockshin B, "Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis", J Am Acad Dermatol, 79, pp.345~352 (2018)
6. Mehta NN, "Attributable risk estimate of severe psoriasis on major cardiovascular events", Am J Med, 124, pp.775~ (2011)
7. Eder L, "The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease", Ann Rheum Dis, 73, pp.1990~1996 (2014)
8. Naldi L, "The clinical spectrum of psoriasis", Clin Dermatol, 25, pp.510~518 (2007)
9. Yeung H, "Psoriasis severity and the prevalence of major medical comorbidity : a population-based study", JAMA Dermatol, 149, pp.1173~1179 (2013)
10. Raychaudhuri SK, "Diagnosis and classification of psoriasis", Autoimmun Rev, 13, pp.490~495 (2014)
11. McDonald CJ, "Occlusive vascular disease in psoriatic patients", N Engl J Med, 288, pp.912~ (1973)
12. Samarasekera EJ, "Incidence of cardiovascular disease in individuals with psoriasis : a systematic review and meta-analysis", J Invest Dermatol, 133, pp.2340~2346 (2013)
13. Jung KJ, "Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea : a 15-year nationwide population-based cohort study", J Dermatol, 46, pp.859~866 (2019)
14. Morici N, "Psoriasis and the risk of acute coronary syndrome in the elderly", Int J Cardiol, 273, pp.44~46 (2018)
15. Hu SC, "Increased incidence of ischaemic heart disease and cerebrovascular disease in psoriasis patients with depression : a nationwide retrospective cohort study", J Eur Acad Dermatol Venereol, 33, pp.1547~1554 (2019)
16. Dhana A, "All-cause and cause-specific mortality in psoriasis : a systematic review and meta-analysis", J Am Acad Dermatol, 80, pp.1332~1343 (2019)
17. Hu SC, "Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment", Int J Mol Sci, 18, pp.2211~ (2017)
18. Spah F, "Inflammation in atherosclerosis and psoriasis : common pathogenic mechanisms and the potential for an integrated treatment approach", Br J Dermatol, 159(Suppl 2), pp.10~17 (2008)
19. Mahyoodeen NG, "Double trouble : psoriasis and cardiometabolic disorders", Cardiovasc J Afr, 29, pp.189~194 (2018)
20. Caiazzo G, "Psoriasis, cardiovascular events, and biologics: lights and shadows", Front Immunol, 9, pp.1668~ (2018)
21. Shaaban D, "The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis : a retrospective study", J Dermatolog Treat, 29, pp.3~7 (2018)
22. Sajja AP, "Potential immunological links between psoriasis and cardiovascular disease", Front Immunol, 9, pp.1234~ (2018)
23. Kremers HM, "Heart disease in psoriasis", J Am Acad Dermatol, 57, pp.347~354 (2007)
24. -fluorodeoxyglucose positron emission tomography, "Circulation", 2002, 2708~2711
25. Hansson GK, "Inflammation, atherosclerosis, and coronary artery disease", N Engl J Med, 352, pp.1685~1695 (2005)
26. Packer M, "Epicardial adipose tissue inflammation can cause the distinctive pattern of cardiovascular disorders seen in psoriasis", Am J Med, 133, pp.267~272 (2020)
27. Playford MP, "Serum active 1,25(OH)2D, but not inactive 25(OH)D vitamin D levels are associated with cardiometabolic and cardiovascular disease risk in psoriasis", Atherosclerosis, 289, pp.44~50 (2019)
28. Ergun T, "Advanced glycation end products, a potential link between psoriasis and cardiovascular disease: a case-control study", Indian J Dermatol, 64, pp.201~206 (2019)
29. Pietrzak A, "Serum lipid metabolism in psoriasis and psoriatic arthritis : an update", Arch Med Sci, 15, pp.369~375 (2019)
30. Sorokin AV, "Association between oxidation-modified lipoproteins and coronary plaque in psoriasis", Circ Res, 123, pp.1244~1254 (2018)
31. Blegvad C, "Psoriasis as a predictor of cardiometabolic comorbidity in women : a study based on the Danish National Birth Cohort", Acta Derm Venereol, 99, pp.274~278 (2019)
32. Dickison P, "Non-invasive measurements to stratify cardiovascular disease risk in psoriasis patients", Aust J Gen Pract, 47, pp.299~304 (2018)
33. Fernandez-Armenteros JM, "Psoriasis, metabolic syndrome and cardiovascular risk factors: a population-based study", J Eur Acad Dermatol Venereol, 33, pp.128~135 (2019)
34. Lloyd-Jones DM, "Framingham risk score and prediction of lifetime risk for coronary heart disease", Am J Cardiol, 94, pp.20~24 (2004)
35. Akosah KO, "Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?", J Am Coll Cardiol, 41, pp.1475~1479 (2003)
36. Fernandez-Torres R, "Psoriasis and cardiovascular risk : assessment by different cardiovascular risk scores", J Eur Acad Dermatol Venereol, 27, pp.1566~1570 (2013)
37. Koku Aksu AE, "Age and gender differences in Framingham risk score and metabolic syndrome in psoriasis patients : a cross-sectional study in the Turkish population", Anatol J Cardiol, 17, pp.66~72 (2017)
38. Gyldenlove M, "Psoriasis and the Framingham risk score in a Danish hospital cohort", Int J Dermatol, 53, pp.1086~1090 (2014)
39. Navarini L, "Performances of five risk algorithms in predicting cardiovascular events in patients with psoriatic arthritis: an Italian bicentric study", PLoS One, 13, pp.e0205506~ (2018)
40. El-Mongy S, "Subclinical atherosclerosis in patients with chronic psoriasis: a potential association", J Eur Acad Dermatol Venereol, 24, pp.661~666 (2010)
41. Gonzalez-Cantero A, "Subclinical atherosclerosis in psoriasis: usefulness of femoral artery ultrasound for the diagnosis, and analysis of its relationship with insulin resistance", PLoS One, 14, pp.e0211808~ (2019)
42. Piaserico S, "Long-term prognostic value of coronary flow reserve in psoriasis patients", Atherosclerosis, 289, pp.57~63 (2019)
43. Elnabawi YA, "Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index", JAMA Cardiol, 4, pp.885~891 (2019)
44. Gorga E, "Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis : a case-control study", Monaldi Arch Chest Dis, 88, pp.934~ (2018)
45. Staniak HL, "Association between psoriasis and coronary calcium score", Atherosclerosis, 237, pp.847~852 (2014)
46. Rueda-Gotor J, "Cardiovascular risk stratification in axial spondyloarthritis : carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients", Clin Exp Rheumatol, 36, pp.73~80 (2018)
47. -fluorodeoxyglucose positron emission tomography-computed tomography(FDG-PET, "CT) : a pilot study", Arch Dermatol, 147, pp.1031~1039 (2011)
48. Rose S, "A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET", CT: a pilot study, 2013, pp.3, 273~278
49. Youn SW, "Subclinical systemic and vascular inflammation detected by(18)F-fluorodeoxyglucose positron emission tomography", computed tomography in patients with mild psoriasis, 2015, pp.42, 559~566
50. Shahidi-Dadras M, "Can serum level of N-terminal pro B-type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease?", Dermatol Ther, 32, pp.e12865~ (2019)
51. Curco N, "Factors influencing cardiometabolic risk profile in patients with psoriasis", Australas J Dermatol, 59, pp.e93~e98 (2018)
52. Kotwica T, "Role of galectin-3 in subclinical myocardial impairment in psoriasis", J Eur Acad Dermatol Venereol, 33, pp.136~142 (2019)
53. Libby P, "Inflammation in atherosclerosis : from pathophysiology to practice", J Am Coll Cardiol, 54, pp.2129~2138 (2009)
54. Micha R, "Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease", Am J Cardiol, 108, pp.1362~1370 (2011)
55. Prodanovich S, "Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis", J Am Acad Dermatol, 52, pp.262~267 (2005)
56. Vena GA, "Psoriasis and cardiovascular disease", Dermatol Ther, 23, pp.144~151 (2010)
57. Casserly CM, "Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis", J Am Acad Dermatol, 29, pp.477~480 (1993)
58. Lan CC, "Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients : a nationwide population-based study", Acta Derm Venereol, 92, pp.349~352 (2012)
59. Balanescu AR, "Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases", Exp Ther Med, 17, pp.1024~1029 (2019)
60. Russell G, "Mechanisms of action of cyclosporine and effects on connective tissues", Semin Arthritis Rheum, 21(6 Suppl 3), pp.16~22 (1992)
61. Colombo MD, "Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches", ScientificWorldJournal, 2013, pp.805705~ (2013)
62. Wakkee M, "Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients", Atherosclerosis, 190, pp.1~9 (2007)
63. Pietrzak A, "Cardiovascular aspects of psoriasis : an updated review", Int J Dermatol, 52, pp.153~162 (2013)
64. Hugh J, "From the Medical Board of the National Psoriasis Foundation : the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies", J Am Acad Dermatol, 70, pp.168~177 (2014)
65. Stern RS, "The safety of etretinate as long-term therapy for psoriasis : results of the etretinate follow-up study", J Am Acad Dermatol, 33, pp.44~52 (1995)
66. Robinson KP, "Colchicine in dermatology : a review", Australas J Dermatol, 59, pp.278~285 (2018)
67. Sator P, "Safety and tolerability of adalimumab for the treatment of psoriasis : a review summarizing 15 years of real-life experience", Ther Adv Chronic Dis, 9, pp.147~158 (2018)
68. Boehncke S, "Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk : results of a prospective longitudinal observational study", J Eur Acad Dermatol Venereol, 25, pp.1187~1193 (2011)
69. Mehta NN, "Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial", Circ Cardiovasc Imaging, 11, pp.e007394~ (2018)
70. Rask L, "The complete amino acid sequence of human serum retinol-binding protein", Ups J Med Sci, 92, pp.115~146 (1987)
71. Pina T, "Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis : a 6-month prospective study", J Eur Acad Dermatol Venereol, 29, pp.1325~1330 (2015)
72. Marra M, "Effect of etanercept on insulin sensitivity in nine patients with psoriasis", Int J Immunopathol Pharmacol, 20, pp.731~736 (2007)
73. Chiricozzi A, "The pharmacological management of patients with comorbid psoriasis and obesity", Expert Opin Pharmacother, 20, pp.863~872 (2019)
74. Uyemura K, "Cross-regulatory roles of interleukin(IL)-12 and IL-10 in atherosclerosis", J Clin Invest, 97, pp.2130~2138 (1996)
75. Lee WK, "Effects of ustekinumab on systemic and vascular inflammation assessed by 18F-FDG PET", CT in Korean patients with moderate to severe psoriasis, 2017, pp.76(6 Suppl 1), AB110~
76. Langley R, "Long-term safety and efficacy of ABT-874 for the treatment of moderate to severe psoriasis: interim analysis from an open-label extension study", J Am Acad Dermatol, 64(2 Suppl 1), pp.AB148~ (2011)
77. Van de Kerkhof PC, "Secukinumab long-term safety experience : a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis", J Am Acad Dermatol, 75, pp.83~98 (2016)
78. Frieder J, "Secukinumab : a review of the antiIL-17A biologic for the treatment of psoriasis", Ther Adv Chronic Dis, 9, pp.5~21 (2018)
79. Egeberg A, "Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3", J Am Acad Dermatol, 79, pp.104~109 (2018)
80. Strober B, "Overview of adverse cardiovascular events in the brodalumab psoriasis studies", J Am Acad Dermatol, 76(6 Suppl 1), pp.AB186~ (2017)
81. Reich K, "Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks : a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies", Br J Dermatol, 180, pp.1039~1049 (2019)
82. Ridker PM, "Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab : a secondary analysis from the CANTOS randomised controlled trial", Lancet, 391, pp.319~328 (2018)
83. Tsai YC, "Anti-interleukin and interleukin therapies for psoriasis : current evidence and clinical usefulness", Ther Adv Musculoskelet Dis, 9, pp.277~294 (2017)
84. Saurat JH, "Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)", Br J Dermatol, 158, pp.558~566 (2008)
85. Guenther LC, "Acitretin use in dermatology", J Cutan Med Surg, 21(3_suppl), pp.2S~12S (2017)
86. Borghi A, "Low-dose acitretin in treatment of plaque-type psoriasis : descriptive study of efficacy and safety", Acta Derm Venereol, 95, pp.332~336 (2015)
87. Chen K, "Teaching an old dog new tricks : colchicine in cardiovascular medicine", Am J Cardiovasc Drugs, 17, pp.347~360 (2017)
88. Papp KA, "Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment : results from a randomized phase III study", J Eur Acad Dermatol Venereol, 28, pp.790~798 (2014)
89. Langley RG, "Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up", Br J Dermatol, 172, pp.1371~1383 (2015)
90. Nemoto O, "Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study", Br J Dermatol, 178, pp.689~696 (2018)
91. Prinz JC, "Treatment of psoriasis with etanercept : the typical patient profile", J Eur Acad Dermatol Venereol, 30, pp.1092~1099 (2016)
92. Burness CB, "Adalimumab : a review in chronic plaque psoriasis", Drugs, 75, pp.2119~2130 (2015)
93. Tausend W, "Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab", J Cutan Med Surg, 18, pp.156~169 (2014)
94. Mansouri B, "Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab", Clin Exp Dermatol, 41, pp.324~326 (2016)
95. Fiolet AT, "Colchicine in stable coronary artery disease", Clin Ther, 41, pp.30~40 (2019)
96. Nidorf SM, "Low-dose colchicine for secondary prevention of cardiovascular disease", J Am Coll Cardiol, 61, pp.404~410 (2013)
97. Weger W, "Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents", Br J Pharmacol, 160, pp.810~820 (2010)
98. Ronholt K, "Old and new biological therapies for psoriasis", Int J Mol Sci, 18, pp.2297~ (2017)
99. Rungapiromnan W, "Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis : systematic review and meta-analysis of randomized controlled trials", Br J Dermatol, 176, pp.890~901 (2017)
100. Pina T, "Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis : a 6-month prospective study", J Eur Acad Dermatol Venereol 2016;, 30, pp.92~95 (2016)
101. Ridker PM, "Antiinflammatory therapy with canakinumab for atherosclerotic disease", N Engl J Med, 377, pp.1119~1131 (2017)
102. Choudhury RP, "Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance", J Am Coll Cardiol, 68, pp.1769~1780 (2016)
103. Kimball AB, "National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening", J Am Acad Dermatol, 58, pp.1031~1042 (2008)
104. Dauden E, "Integrated approach to comorbidity in patients with psoriasis", Actas Dermosifiliogr, 1, pp.1~64 (2012)
105. Eder L, "Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease : an international multicenter study", J Rheumatol, 45, pp.378~384 (2018)
106. Semb AG, "Optimization of CVD prevention in psoriatic arthritis", Nat Rev Rheumatol, 14, pp.323~324 (2018)
107. Phan C, "Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis : results from the NutriNetSante cohort", JAMA Dermatol, 154, pp.1017~1024 (2018)
108. Molina-Leyva A, "Adherence to Mediterranean diet in Spanish patients with psoriasis: cardiovascular benefits?", Dermatol Ther, 32, pp.e12810~ (2019)

관련 논문AI추천